Clinical Trials - April 20, 2015
Active Biotech Shares Plunge
Shares of Ipsen and partner Active Biotech plunged last week after Ipsen’s experimental prostate cancer drug Tasquinimod failed during a Phase III trial. Active’s shares dropped 60 percent and Ipsen’s went down by 10 percent. “The data at hand is unambiguous and cannot motivate further development of tasquinimod in this patient population,” said Tomas Leanderson, […]
Collaboration - April 20, 2015
PCI Partners With U.S. Firm
Norway’s PCI Biotech is initiating a pre-clinical research collaboration with American biotechnology company RXi Pharmaceuticals. The purpose of the pre-clinical research collaboration “is to utilize the companies’ complementary scientific platforms to explore potential synergies,” according to information from PCI Biotech. The partnership will evaluate technology compatibility based on in vitro and in vivo studies. Each […]
Uncategorized - April 20, 2015
Exercise Slows Alzheimer’s
A new study from the research project ADEX at the University of Copenhagen shows that just one hour of moderate physical exercise three times a week can slow the development of Alzheimer’s disease when it is at its earliest stages, according to ScienceNordic. “We’ve known for a long time that physical activity reduces the risk […]
Pharma Business - April 17, 2015
Novo Opens Russian Facility
Novo Nordisk has opened a new manufacturing facility in the Kaluga region of Russia for the production of modern devices for administering insulin for treating diabetes. The facility will produce both Penfill® cartridges and FlexPen® prefilled insulin injection pens for the Russian market, according to FiercePharma. The new facility is located in Technopark Grabtsevo and […]
Pharma Business - April 16, 2015
Recipharm Invests in Synthonics
Recipharm has made an equity investment in Synthonics Inc. and purchased $2.0 million of preferred stock in the company. An additional $2.0 million of preferred stock is expected to be purchased upon Synthonics’ achievement of certain milestones, which could occur during 2016, according to information from Recipharm. Synthonics and Recipharm also have entered into a […]
Clinical Trials - April 16, 2015
Renal Disease Drug Nails Trial
The NEFIGAN Trial of Pharmalink AB’s Nefecon®, a drug for the treatment of primary IgA nephropathy, was stopped early because the drug fully met its primary efficacy endpoint at a planned interim analysis, according to news from BioSpace.com. The interim analysis, conducted by the Data & Safety Monitoring Board (DSMB), showed that Nefecon treatment, with […]
